🎉 M&A multiples are live!
Check it out!

Longeveron Valuation Multiples

Discover revenue and EBITDA valuation multiples for Longeveron and similar public comparables like Cynata Therapeutics, Lineage Cell Therapeutics, and Arovella Therapeutics.

Longeveron Overview

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty.


Founded

2014

HQ

United States of America
Employees

26

Website

longeveron.com

Financials

LTM Revenue $2.4M

LTM EBITDA n/a

EV

$3.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Longeveron Financials

Longeveron has a last 12-month revenue of $2.4M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Longeveron achieved revenue of $2.4M and an EBITDA of -$15.6M.

Longeveron expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Longeveron valuation multiples based on analyst estimates

Longeveron P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.7M $2.4M XXX XXX XXX
Gross Profit $0.5M $0.2M XXX XXX XXX
Gross Margin 70% 9% XXX XXX XXX
EBITDA -$20.1M -$15.6M XXX XXX XXX
EBITDA Margin -2833% -651% XXX XXX XXX
Net Profit -$18.8M -$21.4M XXX XXX XXX
Net Margin -2657% -895% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Longeveron Stock Performance

As of April 15, 2025, Longeveron's stock price is $1.

Longeveron has current market cap of $21.6M, and EV of $3.8M.

See Longeveron trading valuation data

Longeveron Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.8M $21.6M XXX XXX XXX XXX $-2.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Longeveron Valuation Multiples

As of April 15, 2025, Longeveron has market cap of $21.6M and EV of $3.8M.

Longeveron's trades at 1.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Longeveron's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Longeveron and 10K+ public comps

Longeveron Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.8M XXX XXX XXX
EV/Revenue 1.6x XXX XXX XXX
EV/EBITDA -0.2x XXX XXX XXX
P/E -1.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Longeveron Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Longeveron Valuation Multiples

Longeveron's NTM/LTM revenue growth is 5%

Longeveron's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Longeveron's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Longeveron's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Longeveron and other 10K+ public comps

Longeveron Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 237% XXX XXX XXX XXX
EBITDA Margin -651% XXX XXX XXX XXX
EBITDA Growth -23% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -646% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 429% XXX XXX XXX XXX
R&D Expenses to Revenue 340% XXX XXX XXX XXX
Opex to Revenue 769% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Longeveron Public Comps

See public comps and valuation multiples for Regenerative Medicine and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Longeveron M&A and Investment Activity

Longeveron acquired  XXX companies to date.

Last acquisition by Longeveron was  XXXXXXXX, XXXXX XXXXX XXXXXX . Longeveron acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Longeveron

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Longeveron

When was Longeveron founded? Longeveron was founded in 2014.
Where is Longeveron headquartered? Longeveron is headquartered in United States of America.
How many employees does Longeveron have? As of today, Longeveron has 26 employees.
Who is the CEO of Longeveron? Longeveron's CEO is Mr. Mohamed Wael Ahmed Hashad.
Is Longeveron publicy listed? Yes, Longeveron is a public company listed on NAS.
What is the stock symbol of Longeveron? Longeveron trades under LGVN ticker.
When did Longeveron go public? Longeveron went public in 2021.
Who are competitors of Longeveron? Similar companies to Longeveron include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of Longeveron? Longeveron's current market cap is $21.6M
What is the current revenue of Longeveron? Longeveron's last 12-month revenue is $2.4M.
What is the current EV/Revenue multiple of Longeveron? Current revenue multiple of Longeveron is 1.6x.
What is the current revenue growth of Longeveron? Longeveron revenue growth between 2023 and 2024 was 237%.
Is Longeveron profitable? Yes, Longeveron is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.